Indacaterol/mometasone
Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2 agonists.

The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat). Other common side effects include upper respiratory tract infection (nose and throat infections) and headache. Indacaterol/mometasone was approved for medical use in the European Union in May 2020, and in Japan in June 2020.
Q1779868
fixed-dose combination
Concept
Q35869
asthma
Concept
Q210420
corticosteroids
Concept
Q423482
beta2 agonist
Concept
Q35869
asthma
Concept
Q12125
nasopharyngitis
Concept
Q97355508
Indacaterol/mometasone
Concept
Q97355508
Indacaterol/mometasone
Concept
2020-05-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
May 2020
DATE
2020-06-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
June 2020
DATE
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
instance of